In vivo (R)-[(11)C]PK11195 PET imaging of 18kDa translocator protein in recent onset psychosis

Thalia F. Van Der Doef, Lot D. De Witte, Arjen L. Sutterland, Ellen Jobse, Maqsood Yaqub, Ronald Boellaard, Lieuwe De Haan, Jonas Eriksson, Adriaan A. Lammertsma, René S. Kahn, Bart N.M. Van Berckel

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Evidence is accumulating that immune dysfunction is involved in the pathophysiology of schizophrenia. It has been hypothesized that microglia activation is present in patients with schizophrenia. Various in vivo and post-mortem studies have investigated this hypothesis, but as yet with inconclusive results. Microglia activation is associated with elevations in 18 kDa translocator protein (TSPO) levels, which can be measured with the positron emission tomography (PET) tracer (R)-[(11)C]PK11195. The purpose of the present study was to investigate microglia activation in psychosis in vivo at an early stage of the disease. (R)-[(11)C]PK11195 binding potential (BPND) was measured in 19 patients with recent onset psychosis and 17 age and gender-matched healthy controls. Total gray matter, as well as five gray matter regions of interest (frontal cortex, temporal cortex, parietal cortex, striatum, and thalamus) were defined a priori. PET data were analysed using a reference tissue approach and a supervised cluster analysis algorithm to identify the reference region. No significant difference in (R)-[(11)C]PK11195 BPND between patients and controls was found in total gray matter, nor one of the regions of interest. These findings suggest that microglia activation is not present in recent onset psychosis or that it is a subtle phenomenon that could not be detected using the design of the present study.

Original languageEnglish
Article number16031
JournalSchizophrenia Research
Volume2
DOIs
Publication statusPublished - 31 Aug 2016

Cite this

Van Der Doef, Thalia F. ; De Witte, Lot D. ; Sutterland, Arjen L. ; Jobse, Ellen ; Yaqub, Maqsood ; Boellaard, Ronald ; De Haan, Lieuwe ; Eriksson, Jonas ; Lammertsma, Adriaan A. ; Kahn, René S. ; Van Berckel, Bart N.M. / In vivo (R)-[(11)C]PK11195 PET imaging of 18kDa translocator protein in recent onset psychosis. In: Schizophrenia Research. 2016 ; Vol. 2.
@article{2d0b022528704b38a13cdf91bc38ee47,
title = "In vivo (R)-[(11)C]PK11195 PET imaging of 18kDa translocator protein in recent onset psychosis",
abstract = "Evidence is accumulating that immune dysfunction is involved in the pathophysiology of schizophrenia. It has been hypothesized that microglia activation is present in patients with schizophrenia. Various in vivo and post-mortem studies have investigated this hypothesis, but as yet with inconclusive results. Microglia activation is associated with elevations in 18 kDa translocator protein (TSPO) levels, which can be measured with the positron emission tomography (PET) tracer (R)-[(11)C]PK11195. The purpose of the present study was to investigate microglia activation in psychosis in vivo at an early stage of the disease. (R)-[(11)C]PK11195 binding potential (BPND) was measured in 19 patients with recent onset psychosis and 17 age and gender-matched healthy controls. Total gray matter, as well as five gray matter regions of interest (frontal cortex, temporal cortex, parietal cortex, striatum, and thalamus) were defined a priori. PET data were analysed using a reference tissue approach and a supervised cluster analysis algorithm to identify the reference region. No significant difference in (R)-[(11)C]PK11195 BPND between patients and controls was found in total gray matter, nor one of the regions of interest. These findings suggest that microglia activation is not present in recent onset psychosis or that it is a subtle phenomenon that could not be detected using the design of the present study.",
keywords = "Journal Article",
author = "{Van Der Doef}, {Thalia F.} and {De Witte}, {Lot D.} and Sutterland, {Arjen L.} and Ellen Jobse and Maqsood Yaqub and Ronald Boellaard and {De Haan}, Lieuwe and Jonas Eriksson and Lammertsma, {Adriaan A.} and Kahn, {Ren{\'e} S.} and {Van Berckel}, {Bart N.M.}",
year = "2016",
month = "8",
day = "31",
doi = "10.1038/npjschz.2016.31",
language = "English",
volume = "2",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",

}

In vivo (R)-[(11)C]PK11195 PET imaging of 18kDa translocator protein in recent onset psychosis. / Van Der Doef, Thalia F.; De Witte, Lot D.; Sutterland, Arjen L.; Jobse, Ellen; Yaqub, Maqsood; Boellaard, Ronald; De Haan, Lieuwe; Eriksson, Jonas; Lammertsma, Adriaan A.; Kahn, René S.; Van Berckel, Bart N.M.

In: Schizophrenia Research, Vol. 2, 16031, 31.08.2016.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - In vivo (R)-[(11)C]PK11195 PET imaging of 18kDa translocator protein in recent onset psychosis

AU - Van Der Doef, Thalia F.

AU - De Witte, Lot D.

AU - Sutterland, Arjen L.

AU - Jobse, Ellen

AU - Yaqub, Maqsood

AU - Boellaard, Ronald

AU - De Haan, Lieuwe

AU - Eriksson, Jonas

AU - Lammertsma, Adriaan A.

AU - Kahn, René S.

AU - Van Berckel, Bart N.M.

PY - 2016/8/31

Y1 - 2016/8/31

N2 - Evidence is accumulating that immune dysfunction is involved in the pathophysiology of schizophrenia. It has been hypothesized that microglia activation is present in patients with schizophrenia. Various in vivo and post-mortem studies have investigated this hypothesis, but as yet with inconclusive results. Microglia activation is associated with elevations in 18 kDa translocator protein (TSPO) levels, which can be measured with the positron emission tomography (PET) tracer (R)-[(11)C]PK11195. The purpose of the present study was to investigate microglia activation in psychosis in vivo at an early stage of the disease. (R)-[(11)C]PK11195 binding potential (BPND) was measured in 19 patients with recent onset psychosis and 17 age and gender-matched healthy controls. Total gray matter, as well as five gray matter regions of interest (frontal cortex, temporal cortex, parietal cortex, striatum, and thalamus) were defined a priori. PET data were analysed using a reference tissue approach and a supervised cluster analysis algorithm to identify the reference region. No significant difference in (R)-[(11)C]PK11195 BPND between patients and controls was found in total gray matter, nor one of the regions of interest. These findings suggest that microglia activation is not present in recent onset psychosis or that it is a subtle phenomenon that could not be detected using the design of the present study.

AB - Evidence is accumulating that immune dysfunction is involved in the pathophysiology of schizophrenia. It has been hypothesized that microglia activation is present in patients with schizophrenia. Various in vivo and post-mortem studies have investigated this hypothesis, but as yet with inconclusive results. Microglia activation is associated with elevations in 18 kDa translocator protein (TSPO) levels, which can be measured with the positron emission tomography (PET) tracer (R)-[(11)C]PK11195. The purpose of the present study was to investigate microglia activation in psychosis in vivo at an early stage of the disease. (R)-[(11)C]PK11195 binding potential (BPND) was measured in 19 patients with recent onset psychosis and 17 age and gender-matched healthy controls. Total gray matter, as well as five gray matter regions of interest (frontal cortex, temporal cortex, parietal cortex, striatum, and thalamus) were defined a priori. PET data were analysed using a reference tissue approach and a supervised cluster analysis algorithm to identify the reference region. No significant difference in (R)-[(11)C]PK11195 BPND between patients and controls was found in total gray matter, nor one of the regions of interest. These findings suggest that microglia activation is not present in recent onset psychosis or that it is a subtle phenomenon that could not be detected using the design of the present study.

KW - Journal Article

UR - http://www.scopus.com/inward/record.url?scp=85011861222&partnerID=8YFLogxK

U2 - 10.1038/npjschz.2016.31

DO - 10.1038/npjschz.2016.31

M3 - Article

VL - 2

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

M1 - 16031

ER -